Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering. On April 1, Autolus said that after one month, CD19-targeting AUTO1 led to molecular complete responses in eight of nine evaluable patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL). At five months, six of 10 were alive and in molecular remission. Source: Biocentury 11/4/2019